PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)--Regulatory News: In continuation of their joint company announcement of July 23, 2014, BioAlliance Pharma SA (Paris:BIO) (Euronext Paris – BIO), an innovative company specialized in the development of drugs in orphan oncology diseases newly renamed Onxeo, and Topotarget A/S (NASDAQ OMX Copenhagen – TOPO), today announce that NASDAQ OMX Copenhagen has approved Onxeo’s admission to secondary trading and official listing on NASDAQ OMX Copenhagen to be effective as of August 1, 2014. From this date, BioAlliance Pharma as the continuing entity after the merger will also officially operate under the name Onxeo.
Help employers find you! Check out all the jobs and post your resume.
